<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04986540</url>
  </required_header>
  <id_info>
    <org_study_id>SHR-1906-101</org_study_id>
    <nct_id>NCT04986540</nct_id>
  </id_info>
  <brief_title>A Trial of SHR - 1906 in Healthy Subjects</brief_title>
  <official_title>A Phase 1, Randomized, Double-Blind, Placebo-Controlled Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single IV Infusion of SHR-1906 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangdong Hengrui Pharmaceutical Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangdong Hengrui Pharmaceutical Co., Ltd</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a phase 1 single dose escalation study of SHR-1906 in healthy subjects. The&#xD;
      purpose of the study is to evaluate the safety, tolerability and pharmacokinetics of SHR-1906&#xD;
      in healthy subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 30, 2021</start_date>
  <completion_date type="Anticipated">February 9, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 9, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>SHR-1906 compared with placebo</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Start of Treatment to end of study (approximately 10 weeks)</time_frame>
    <description>Incidence and severity of adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics-AUC0-last</measure>
    <time_frame>Start of Treatment to end of study (approximately 10 weeks)</time_frame>
    <description>Area under the concentration-time curve from time 0 to last time point after SHR-1906 administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics-AUC0-inf</measure>
    <time_frame>Start of Treatment to end of study (approximately 10 weeks)</time_frame>
    <description>Area under the concentration-time curve from time 0 to infinity after SHR-1906 administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics-Tmax</measure>
    <time_frame>Start of Treatment to end of study (approximately 10 weeks)</time_frame>
    <description>Time to Cmax of SHR-1906</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics-Cmax</measure>
    <time_frame>Start of Treatment to end of study (approximately 10 weeks)</time_frame>
    <description>Maximum observed concentration of SHR-1906</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics-CL</measure>
    <time_frame>Start of Treatment to end of study (approximately 10 weeks)</time_frame>
    <description>Clearance of SHR-1906</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics-V</measure>
    <time_frame>Start of Treatment to end of study (approximately 10 weeks)</time_frame>
    <description>Volume of distribution during terminal phase of SHR-1906</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics-t1/2</measure>
    <time_frame>Start of Treatment to end of study (approximately 10 weeks)</time_frame>
    <description>Terminal elimination half-life of SHR-1906</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-Drug antibody</measure>
    <time_frame>Start of Treatment to end of study (approximately 10 weeks)</time_frame>
    <description>The percentage of subjects with positive ADA titers over time for SHR-1906</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single subcutaneous injection of SHR-1906/placebo dose 1 in healthy subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single subcutaneous injection of SHR-1906/placebo dose 2 in healthy subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single subcutaneous injection of SHR-1906/placebo dose 3 in healthy subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single subcutaneous injection of SHR-1906/placebo dose 4 in healthy subjects</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR-1906；Placebo</intervention_name>
    <description>Drug: SHR-1906 IV, single dose&#xD;
Drug: Placebo IV, single dose</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Ability to understand the trial procedures and possible adverse events, volunteers to&#xD;
             participate in the trial, and provides written informed consent, be able to comply&#xD;
             with all the requirements and able to complete the study.&#xD;
&#xD;
          2. Male or female aged between 18 years and 55 years (inclusive) at the date of signed&#xD;
             consent form.&#xD;
&#xD;
          3. Total body weight ≥ 45 kg.&#xD;
&#xD;
          4. No clinically significant abnormalities in medical history, general physical&#xD;
             examination, vital signs, laboratory tests (hematology, urinalysis, blood chemistry,&#xD;
             coagulation function and thyroid function) and ECG at the investigator's discretion&#xD;
             during screening and baseline&#xD;
&#xD;
          5. Men and women of childbearing potential (WOCBP) must agree to take effective&#xD;
             contraceptive methods&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of serious cardiovascular, liver, kidney, digestive tract, psychiatric,&#xD;
             hematology, metabolic disorders, primary immunodeficiency disease or acquired immune&#xD;
             deficiency syndrome, or organ transplantation.&#xD;
&#xD;
          2. Severe infections, injuries or major surgeries (as determined by the investigator)&#xD;
             within 6 months prior to screening, or plan to do any surgery during the trial.&#xD;
&#xD;
          3. Positive testing for human immunodeficiency virus (HIV-Ab), or hepatitis B surface&#xD;
             antigen (HBsAg), or TP-Ab , or hepatitis C antibodies (HCV-Ab).&#xD;
&#xD;
          4. Screening/baseline systolic blood pressure (BP) ≥140 mmHg or ≤90 mmHg; diastolic BP&#xD;
             ≥90 mmHg or &lt;60 mmHg on a single measurement&#xD;
&#xD;
          5. Positive urine drug screening at baseline;&#xD;
&#xD;
          6. Use of any medicine within 1 monthes (including any prescription, or over-the-counter&#xD;
             medicine, herbal remedy or nutritional supplement, except for vitamins and occasional&#xD;
             use of acetaminophen with recommended dose), or within 5 half-lives of any drugs&#xD;
             whichever is longer prior to dosing, or plan to use any medicine during the trial.&#xD;
&#xD;
          7. Participation in clinical trials of other investigational drugs or medical devices&#xD;
             within 3 months prior to screening or within 5 half-lives of any drugs during&#xD;
             screening visit, or in the follow-up period of a clinical study whichever is longer&#xD;
             (according to the date of signed consent form) which is defined as having consented&#xD;
             and used other investigational drugs (including placebo) or trial medical devices.&#xD;
&#xD;
          8. Blood donation or loss of ≥ 400 mL of blood within 1 months; or received blood or&#xD;
             blood products within 2 months prior to screening.&#xD;
&#xD;
          9. Any other circumstances that, in the investigator's judgment, may increase the risk&#xD;
             associated with the subject's participation in and completion of the study or could&#xD;
             preclude the evaluation of the subject's response.&#xD;
&#xD;
         10. Researchers and relevant staff of the research center or other persons directly&#xD;
             involved in the implementation of the program.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xiaoyu Yang</last_name>
    <phone>+86 18818211895</phone>
    <email>xiaoyu.yang@hengrui.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lihong Zhuang</last_name>
    <phone>+86 13918926960</phone>
    <email>lihong.zhuang@hengrui.com</email>
  </overall_contact_backup>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 27, 2021</study_first_submitted>
  <study_first_submitted_qc>July 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 3, 2021</study_first_posted>
  <last_update_submitted>July 27, 2021</last_update_submitted>
  <last_update_submitted_qc>July 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

